Latest News

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia
Clinical Trials COVID-19

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Shots: The P-III EMPACTA study involves assessing of Actemra + SOC vs PBO + SOC in 389 patients aged > 18yrs. with confirmed SARS-CoV-2 (COVID-19) infection with SpO2 <94% while on ambient air who did

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies
COVID-19 MedTech

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Shots: Roche has launched Elecsys Anti-SARS-CoV-2 S Ab for markets accepting the CE Mark. The company has filed for US FDA’s EUA The test can quantitatively measure the level of Abs against SARS-CoV-2 in patients

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies
Biotech COVID-19

Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Shots: The companies enter in a global Ab manufacturing collaboration to expedite the global supply of Lilly’s COVID-19 therapies  With the agreement, the two companies will have the ability to ramp up the production and

AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program
M&A

AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program

Shots: Dogma to receive upfront along with global regulatory and commercial milestones. AstraZeneca to get the rights to an orally active drug inhibiting PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that are delivered

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020
Pharma

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Shots: Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme, CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program, and the data from the registrational P-I/II

Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications
Pharma

Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications

Shots: Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the net profit of the therapies

Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients
Clinical Trials COVID-19

Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients

Shots: Sorrento receives the US FDA’s clearance to proceed P-I clinical study of STI-1499 (COVI-GUARD) in hospitalized COVID-19 patients. The company receives the FDA’s notice to proceed the patient enrollment The trial is anticipated to

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020
Biosimilars Clinical Trials

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Shots: The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin, q3w up to 6 cycles followed by Aybintio or reference bevacizumab as

Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU
MedTech

Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU

Shots: Baxter will be the exclusive distributor of bioMérieux’s NEPHROCLEAR CCL14 test in the EU and the US following regulatory approval and launch in both territories. The companies will share in-country commercialization, while bioMérieux will